Sign inJoin waitlistJoin the waitlist

Takeo Fujii

Head, Translational Brain Metastasis and Therapeutics Section · National Cancer Institute, Center for Cancer Research, Women's Malignancies Branch

Credentials: · · · · · · ·

History

Translational Brain Metastasis and Therapeutics Section · National Cancer Institute, Center for Cancer Research, Women's Malignancies Branch
Present

St. Luke’s International Hospital
2025–2027
Cold Spring Harbor Laboratory/Hofstra Northwell Health
2022–2025
Internal Medicine
University of Hawaii John A Burns School of Medicine
2016–2019
The University of Texas MD Anderson Cancer Center
2015–2016
St. Luke’s International Hospital
2012–2015
University of Hawai
2009–2012
United States Naval Hospital Okinawa
2008–2009
University of Texas Health Science Center at Houston School of Public Health
Shinshu University School of Medicine
2003–2007

Research

Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review
Review · JAMA Oncology · 2017 · 178 citations
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
Investigational New Drugs · 2018 · First of 22 authors · 148 citations
Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer
Annals of Oncology · 2017 · First of 13 authors · 136 citations

Naoto Ueno
29 papers
Bora Lim
8 papers · 5 as a fellow
SL
Stanley Lipkowitz
7 papers
Vicente Valero
7 papers
Funda Meric-Bernstam
6 papers
Mariana Mac Gregor
6 papers
Gabriel Hortobagyi
5 papers
Jennifer Litton
5 papers
Aung Naing
4 papers
Aysegul Sahin
4 papers
Carlos Barcenas
4 papers
DT
Debasish Tripathy
4 papers

Grants

Elucidating the Role of Inflammation in Breast Cancer Metastasis
National Cancer Institute · ZIA
Contact PI · $2.2M · Division of Basic Sciences - Nci

Clinical trials

Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Principal investigator · Recruiting
National Cancer Institute (NCI)
2026–2034
Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies
Principal investigator · Enrolling by invitation
National Cancer Institute (NCI)
2022–2028
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Principal investigator · Active not recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2015–2027